Growth Hormone Drugs Market Set To Grow To $4.6 Bn By 2021

07 August 2018
Pharma

Visiongain’ has launched a new Pharmaceutical Report Global Growth Hormone Drugs Market Forecast to 2027: Somatropin and Mecasermin Based Drugs, Innovator Generics and Biosimilars, Norditropin, Genotropin, Humatrope, Saizen, Nutropin, Omnitrope, Zomacton, R&D and Leading Companies

The report forecasts the overall growth hormone drugs market will multiply in revenues from 2017 to 2027. The pharmaceutical segment is evolving. Visiongain reports the strength of the growth hormone drugs market is its somatropin based drugs, factors driving the submarket include anticipated launch of late-stage long acting somatropins. However, the market might witness various challenges such as loss of patent protection for Increlex and Norditropin, allowance of biosimilar substitution, high cost of therapy, and high rate of failure of late-stage clinical trials.

Steady growth is predicted for the growth hormone drugs market during the forecast period of this report. This is primarily due to the strong pipeline for growth hormones deficiency and the approval of long acting hormone drugs that will replace the daily growth hormone drugs, increasing healthcare expenditures, rising incidences of growth hormone deficiency disorders. Other contributing factors include favourable regulatory environment and shift in focus towards auto-injector delivery devices. Several drugs are expected to be approved during the forecast period.

The visiongain report analyst commented ‘’The Global Growth Hormone Drugs Market will see strong growth over the forecast period driven by increasing healthcare expenditures, rising incidences of growth hormone deficiency disorders, favourable regulatory environment and shift in focus towards auto-injector delivery devices. While innovator drugs continue to lead the market over the forecast period, the biosimilar market will witness higher growth as more innovator drugs come off patent. The Growth Hormone Drugs pipeline includes Long acting growth hormone drugs that are expected to replace the daily growth hormones and are anticipated to capture majority of the market share by 2027. On a global context, the US will remain the largest market while emerging markets will see the highest rate of growth’’

The new report shows revenue forecasts to 2027 at overall world market, submarket, product and national level. It forecasts these world-level submarkets:

• Mecasermin based drugs
• Somatropin based drugs
• Innovator Generics
• Biosimilars

This investigation predicts revenues of seven leading products in the market including Norditropin, Genotropin, Humatrope, Saizen, Nutropin, Omnitrope, Zomactan. Tev-tropin/ Growject. Revenue forecasts are also included of Research, data and analyses covering activities of Merck KGaA, Roche, Novartis, Novo Nordisk, Eli Lilly and Co., Pfizer Inc.

Analyses cover R&D and commercial news and predict revenues to 2027 in leading regional markets. This includes the US, Japan, Germany, the UK, France, Italy, and Spain (EU5 group).

Global Growth Hormone Drugs Market: World Industry, R&D and Market Forecasts 2017-2027 adds to visiongain’s range of reports on industries and markets in healthcare. Together these studies cover medical devices, diagnostics and pharmaceuticals.

Leading companies featured in the report who are developing Growth Hormone Drugs include
Merck KGaA, Roche, Novartis, Novo Nordisk, Eli Lilly and Co., Pfizer Inc.

Notes for Editors
If you are interested in a more detailed overview of this report, please send an e-mail to sara.peerun@visiongainglobal.com or call her on +44 (0) 207 336 6100

About visiongain
Visiongain is one of the fastest-growing and most innovative independent media companies in Europe. Based in London, UK, visiongain produces a host of business-to-business reports focusing on the automotive, aviation, chemicals, cyber, defence, energy, food & drink, materials, packaging, pharmaceutical and utilities sectors.

Visiongain publishes reports produced by analysts who are qualified experts in their field. Visiongain has firmly established itself as the first port of call for the business professional who needs independent, high-quality, original material to rely and depend on.

Recent News

“Global Ophthalmic Drugs market set to grow to $33bn by 2024” says new Visiongain report

The market for ophthalmic drugs is a growing one.

17 June 2019

Read

“Generic Drugs market set to grow to $424bn by 2024” says new Visiongain report

Visiongain believes the market will see more traditional pharma companies beginning to embrace the generic business in order to take advantage of higher growth rates in this area.

14 June 2019

Read

“Global Precision Cancer Diagnostic Tests market set to grow to $21.3bn by 2024” says new Visiongain report

The market players are increasingly focusing on precision therapies where drug and precision tests are developed simultaneously.

06 June 2019

Read

“Global Antifungal Drugs market set to grow to $17bn by 2024” says new Visiongain report

Market penetration and adoption of new technologies entering the market for antifungal drugs will be crucial for market growth.

04 June 2019

Read

Kelloggs
3m
Thales
Shell
TEVA
Lockheed-Martin
Pfizer
Raytheon
Halliburton
Du-Pont
Honeywell
Daimler
BASF
Bayer
BP
BAE-Systems
Unilever